Pegozafermin
- Generic Name
- Pegozafermin
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Phase 3
Recruiting
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 762
- Registration Number
- NCT06419374
- Locations
- π¬π§
89bio Clinical Study Site, Southampton, United Kingdom
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Phase 3
Recruiting
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Other: Placebo
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 1050
- Registration Number
- NCT06318169
- Locations
- π¬π§
89bio Clinical Study Site, York, United Kingdom
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
Phase 3
Active, not recruiting
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT05852431
- Locations
- π¬π§
89bio Clinical Study Site, Cardiff, United Kingdom
π΅π·89Bio Clinical Study Site, San Juan, Puerto Rico
π±π»89bio Clinical Trial Site, Riga, Latvia
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05022693
- Locations
- πΊπΈ
89bio Clinical Study Site, Chandler, Arizona, United States
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
Phase 2
Completed
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT04929483
- Locations
- π΅π·
89bio Clinical Study Site, San Juan, Puerto Rico
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT04541186
- Locations
- π΅π±
89Bio Clinical Study Site, ToruΕ, Poland
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- 89bio, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04048135
- Locations
- π΅π·
89bio Clinical Study Site, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath